Maladie du greffon contre l'hôte : Questions médicales fréquentes
Nom anglais: Graft vs Host Disease
Descriptor UI:D006086
Tree Number:C20.452
Termes MeSH sélectionnés :
Tibia
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Maladie du greffon contre l'hôte : Questions médicales les plus fréquentes",
"headline": "Maladie du greffon contre l'hôte : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Maladie du greffon contre l'hôte : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-17",
"dateModified": "2025-02-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Maladie du greffon contre l'hôte"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Maladies du système immunitaire",
"url": "https://questionsmedicales.fr/mesh/D007154",
"about": {
"@type": "MedicalCondition",
"name": "Maladies du système immunitaire",
"code": {
"@type": "MedicalCode",
"code": "D007154",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Syndrome de bronchiolite oblitérante",
"alternateName": "Bronchiolitis Obliterans Syndrome",
"url": "https://questionsmedicales.fr/mesh/D000092122",
"about": {
"@type": "MedicalCondition",
"name": "Syndrome de bronchiolite oblitérante",
"code": {
"@type": "MedicalCode",
"code": "D000092122",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.452.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Maladie du greffon contre l'hôte",
"alternateName": "Graft vs Host Disease",
"code": {
"@type": "MedicalCode",
"code": "D006086",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Stephanie J Lee",
"url": "https://questionsmedicales.fr/author/Stephanie%20J%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington."
}
},
{
"@type": "Person",
"name": "Betty K Hamilton",
"url": "https://questionsmedicales.fr/author/Betty%20K%20Hamilton",
"affiliation": {
"@type": "Organization",
"name": "Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States of America."
}
},
{
"@type": "Person",
"name": "Najla El Jurdi",
"url": "https://questionsmedicales.fr/author/Najla%20El%20Jurdi",
"affiliation": {
"@type": "Organization",
"name": "Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis."
}
},
{
"@type": "Person",
"name": "Steven Z Pavletic",
"url": "https://questionsmedicales.fr/author/Steven%20Z%20Pavletic",
"affiliation": {
"@type": "Organization",
"name": "National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, United States of America."
}
},
{
"@type": "Person",
"name": "Anthony D Sung",
"url": "https://questionsmedicales.fr/author/Anthony%20D%20Sung",
"affiliation": {
"@type": "Organization",
"name": "Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "3D mapping: has the mystery of proximal tibia fractures been solved?",
"datePublished": "2023-03-19",
"url": "https://questionsmedicales.fr/article/36934361",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00590-023-03520-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Relapsed boyhood tibia polymicrobial osteomyelitis linked to dermatophytosis: a case report.",
"datePublished": "2022-05-04",
"url": "https://questionsmedicales.fr/article/35509041",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12893-022-01600-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Guided Growth to Treat Anterolateral Tibial Bowing Associated with Congenital Pseudarthrosis of the Tibia.",
"datePublished": "2024-04-09",
"url": "https://questionsmedicales.fr/article/38835290",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/BPO.0000000000002683"
}
},
{
"@type": "ScholarlyArticle",
"name": "Periprosthetic giant cell tumour of the tibia: en bloc resection and megaprosthesis revision.",
"datePublished": "2024-06-13",
"url": "https://questionsmedicales.fr/article/38871637",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bcr-2024-260631"
}
},
{
"@type": "ScholarlyArticle",
"name": "Does Fibular Displacement Predict Tibial Malrotation in Simulated Tibia-Fibula Fractures.",
"datePublished": "2023-10-16",
"url": "https://questionsmedicales.fr/article/37850972",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5435/JAAOS-D-23-00043"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système immunitaire",
"item": "https://questionsmedicales.fr/mesh/D007154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladie du greffon contre l'hôte",
"item": "https://questionsmedicales.fr/mesh/D006086"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Maladie du greffon contre l'hôte - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Maladie du greffon contre l'hôte",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Maladie du greffon contre l'hôte",
"description": "Comment diagnostiquer la GVHD ?\nQuels tests sont utilisés pour la GVHD ?\nQuels signes cliniques indiquent la GVHD ?\nLa GVHD peut-elle être confondue avec d'autres maladies ?\nQuel rôle joue l'historique médical dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Tibia&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Maladie du greffon contre l'hôte",
"description": "Quels sont les symptômes cutanés de la GVHD ?\nLa GVHD affecte-t-elle le système digestif ?\nQuels symptômes hépatiques sont associés à la GVHD ?\nLa GVHD peut-elle causer des problèmes oculaires ?\nQuels symptômes respiratoires peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Tibia&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Maladie du greffon contre l'hôte",
"description": "Comment prévenir la GVHD après une greffe ?\nLe choix du donneur influence-t-il la GVHD ?\nLes traitements préventifs sont-ils efficaces ?\nLes greffes de cellules souches de sang de cordon sont-elles plus sûres ?\nLes soins post-greffe aident-ils à prévenir la GVHD ?",
"url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Tibia&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Maladie du greffon contre l'hôte",
"description": "Quels traitements sont utilisés pour la GVHD ?\nLa photothérapie est-elle efficace contre la GVHD ?\nLes greffes de cellules souches peuvent-elles aider ?\nQuels médicaments sont prescrits pour la GVHD ?\nLa thérapie cellulaire est-elle une option ?",
"url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Tibia&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Maladie du greffon contre l'hôte",
"description": "Quelles sont les complications de la GVHD ?\nLa GVHD peut-elle entraîner des infections ?\nQuels cancers peuvent survenir après la GVHD ?\nLa GVHD peut-elle affecter la qualité de vie ?\nComment gérer les complications de la GVHD ?",
"url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Tibia&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Maladie du greffon contre l'hôte",
"description": "Quels sont les principaux facteurs de risque de la GVHD ?\nL'âge influence-t-il le risque de GVHD ?\nLe sexe du receveur joue-t-il un rôle ?\nLes antécédents médicaux augmentent-ils le risque ?\nLa source de greffe influence-t-elle le risque ?",
"url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Tibia&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la GVHD ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique et des biopsies cutanées ou intestinales."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour la GVHD ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des biopsies sont effectués pour évaluer l'atteinte des organes."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent la GVHD ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent éruptions cutanées, diarrhée, et atteinte hépatique."
}
},
{
"@type": "Question",
"name": "La GVHD peut-elle être confondue avec d'autres maladies ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec des infections ou d'autres maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique médical dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique de greffe et les traitements antérieurs sont cruciaux pour le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes cutanés de la GVHD ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des éruptions, des démangeaisons et des desquamations."
}
},
{
"@type": "Question",
"name": "La GVHD affecte-t-elle le système digestif ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut provoquer des diarrhées, des douleurs abdominales et des nausées."
}
},
{
"@type": "Question",
"name": "Quels symptômes hépatiques sont associés à la GVHD ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent jaunisse, fatigue et élévation des enzymes hépatiques."
}
},
{
"@type": "Question",
"name": "La GVHD peut-elle causer des problèmes oculaires ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner sécheresse oculaire et inflammation conjonctivale."
}
},
{
"@type": "Question",
"name": "Quels symptômes respiratoires peuvent survenir ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la toux, l'essoufflement et des infections pulmonaires peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment prévenir la GVHD après une greffe ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut l'utilisation d'immunosuppresseurs et le choix de donneurs compatibles."
}
},
{
"@type": "Question",
"name": "Le choix du donneur influence-t-il la GVHD ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un donneur HLA compatible réduit le risque de GVHD."
}
},
{
"@type": "Question",
"name": "Les traitements préventifs sont-ils efficaces ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements préventifs diminuent significativement l'incidence de la GVHD."
}
},
{
"@type": "Question",
"name": "Les greffes de cellules souches de sang de cordon sont-elles plus sûres ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent présenter un risque réduit de GVHD par rapport aux greffes de moelle osseuse."
}
},
{
"@type": "Question",
"name": "Les soins post-greffe aident-ils à prévenir la GVHD ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi médical rigoureux et des soins appropriés sont essentiels."
}
},
{
"@type": "Question",
"name": "Quels traitements sont utilisés pour la GVHD ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des corticostéroïdes et des immunosuppresseurs."
}
},
{
"@type": "Question",
"name": "La photothérapie est-elle efficace contre la GVHD ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la photothérapie peut être utilisée pour traiter les éruptions cutanées."
}
},
{
"@type": "Question",
"name": "Les greffes de cellules souches peuvent-elles aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des greffes supplémentaires peuvent être envisagées dans certains cas de GVHD sévère."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont prescrits pour la GVHD ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme le méthotrexate et la ciclosporine sont souvent prescrits."
}
},
{
"@type": "Question",
"name": "La thérapie cellulaire est-elle une option ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie cellulaire peut être explorée pour des cas réfractaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications de la GVHD ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent infections, défaillance d'organes et cancers secondaires."
}
},
{
"@type": "Question",
"name": "La GVHD peut-elle entraîner des infections ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la GVHD affaiblit le système immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels cancers peuvent survenir après la GVHD ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cancers comme le lymphome et le carcinome peuvent se développer après la GVHD."
}
},
{
"@type": "Question",
"name": "La GVHD peut-elle affecter la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes et complications peuvent gravement impacter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications de la GVHD ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut un suivi médical régulier et des traitements symptomatiques."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque de la GVHD ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, le sexe, et la compatibilité HLA entre donneur et receveur."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de GVHD ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients plus âgés ont un risque accru de développer la GVHD."
}
},
{
"@type": "Question",
"name": "Le sexe du receveur joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les hommes peuvent avoir un risque plus élevé de GVHD que les femmes."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux augmentent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies auto-immunes ou de greffes augmentent le risque."
}
},
{
"@type": "Question",
"name": "La source de greffe influence-t-elle le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les greffes de moelle osseuse présentent un risque plus élevé que celles de sang de cordon."
}
}
]
}
]
}
One of the major limitations of the 2D fracture evaluation (Schatzker classification) is its failure to adequately assess fracture lines in the frontal plane and fracture displacement in the antero-po...
Radiographic data of 228 proximal tibia fractures were retrospectively included in this study. Fracture lines and zones of comminution were graphically superimposed onto a 3D template of an intact tib...
Out of 206 male and 21 female patients, 89 had a fracture of the lateral condyle only (Schatzker I and II), 53 involved the medial plateau only (Schatzker IV) and 86 had a high-grade fracture involvin...
Medial tibial plateau fractures have a mix of coronal or sagittal fracture alignment. A clearer understanding of the 3D orientations of fractures based on CT scans can aid in diagnosing the pattern of...
Relapsed childhood polymicrobial osteomyelitis associated with dermatophytosis has not been reported in the literature....
Here we report on a case of a 45-year-old man who had left tibial osteomyelitis for 29 years, accompanied by skin fungal infection of the ipsilateral heel for 20 years, and underwent a second operatio...
Together with longitudinal follow-up of medical history, surgical findings, histopathological and microbiology culture evidence, we conclude that boyhood tibia polymicrobial osteomyelitis with S. aure...
Anterolateral tibial bowing associated with congenital tibial pseudarthrosis occurs often in patients with neurofibromatosis type 1 and results from the inability of the fractured bone to unite, leadi...
This report describes the management of 3 patients with anterolateral tibial bowing and NF1 who underwent distal tibia-guided growth....
The patients had an average age of 1.6 years at initial operation, with a total of 3 to 4 surgeries over an average of 2.1 years. The latest follow-up on all patients is included, at a mean of 5.1 yea...
Our study indicates that guided growth can serve as an additional surgical option to improve ALTB and potentially reduce the risk of fracture and pseudarthrosis by restoring normal mechanical alignmen...
Level-IV, Case Series....
We present a case detailing the diagnosis and management of a periprosthetic giant cell tumour in a female patient in her 70s, who had undergone total knee arthroplasty (TKA) for primary osteoarthriti...
Tibial malrotation can occur with medullary nailing of diaphyseal tibial fractures. Fibular alignment has been proposed as a surrogate for axial plane reduction intraoperatively. The purpose of this s...
Deidentified CT scans of 50 patients with normal tibial anatomy were selected. Using ImageJ software, we simulated osteotomies at three sites (proximal third, mid-diaphysis, and distal third). We over...
A total of 50 patients were included. The mean age was 62 years, average BMI was 25.8, and 28 of 50 patients (56%) were male. Earliest loss of fibular contact occurred at 24° ER and 22° IR at the prox...
Surgeons should be aware that 20° or more of malrotation is likely present when fibular contact is lost during medullary nailing of the tibia. Greater than 50% loss of contact should raise suspicion f...
Classic metaphyseal lesions (CMLs) should raise concern for nonaccidental trauma. However, iatrogenic causes for CMLs have increasingly been described and warrant close consideration. Increasing the c...
We describe three clinical cases where suspected iatrogenic dorsiflexion or plantar flexion resulted in an isolated distal tibia CML. Respectively, we present heel-stick testing and i.v. line placemen...
Postoperative radiographs are used to monitor fractures of the tibia and femur after intramedullary fixation. This study sought to examine how frequently these radiographs change management....
This was a single-center chart review of patients over a 4-year period at a level I trauma center. Radiographs were defined as either performed for routine surveillance or performed with some clinical...
A total of 374 patients were found. Two hundred seventy-seven received at least one post-op radiograph. The median follow-up was 23 weeks. Six hundred seventeen total radiographs were reviewed. Nine r...
Our results suggest that radiographs taken in the first 3 months post-op in asymptomatic patients treated with lower extremity intramedullary rods do not result in changes to clinical management....
Albeit some studies have revealed the effectiveness of the orthosis use in infantile tibia vara (ITV), hitherto no study has shown the effects of these orthosis on plantar pressures. This study aims t...
Early soft-tissue reconstruction of open fractures has been shown to decrease infection rates and improve rates of bony union. The purpose of this study was to compare the rates and time to union of o...
A retrospective chart review of 118 patients with open tibia fractures requiring soft-tissue reconstruction treated at a single level 1 trauma center was performed. Demographic data as well as flap ty...
Limb salvage was achieved in 90% of patients. The overall rate of nonunion was 33%. Flap type significantly affected time to union, with local fasciocutaneous and keystone flaps having significantly l...
Flap type affects time to union but not nonunion rate in open tibia fractures....
Therapeutic, III....
BACKGROUND Adamantinoma is a rare low-grade malignant bone tumor, usually found in the tibial diaphysis and metaphysis, with histological similarities to mandibular ameloblastoma. The most effective t...